Clinical trial NCT02346240 - References

Psoriasis — Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Citation(s)

•   Lebwohl M, Blauvelt A, Paul C, Sofen H, Weglowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M
  Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-bli
•   Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, Arendt C, Fierens F, Blauvelt A
  Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: Results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermat

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Details for clinical trial NCT02346240